

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

500266 #2

Application of
James M. Warner

)
)
)
)
)

Rec'd PCT/PTO 18 JUN 2004

Attorney Docket No. 01524/1Z

Serial No. TBD

Group Art Unit: Unknown

Filed: June 18, 2004

Examiner: Unknown

For COMBINATION OF A PDE IV INHIBITOR AND A TNF-ALPHA ANTAGONIST

June 18, 2004

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313


SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,



Julie M. Lappin,
Reg. No. 46,612
Attorney for Applicants
(314) 274-2009 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006

Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 01524/1Z US	APPLICATION NO.: TBD 10/500266
	INVENTOR: James M. Warner	
	Filed: 6/18/2004	Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	2002/0103106	8/1/02	Palmer et al	514	1	12/14/01
	2	5712298	1/27/98	Amschler	514	352	7/2/94
	3	6143782	11/7/00	Barnette et al	514	521	5/31/95
	4	6333354	12/25/01	Schudt	514	573	2/24/98
	5	5998428	12/7/99	Barnette et al	514	285	9/3/97

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	6	WO 01/60358	23 August 2001	PCT				
	7	WO 00/66123	9 November 2000	PCT				
	8	WO 01/32127	10 May 2001	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 01524/1Z	APPLICATION NO.: TBD 10/500266
	INVENTOR: James M. Warner	
	Filed: 6/18/2004	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	9	Tracey et al; Annu. Rev. Med; 45; 491-50.3; 1994
	10	Dal Piaz; Eur J Med Chem; 35; 463-480; 2000
	11	Hatzelman et al; J. Pharm Exper. Therap.; 297(1); 267-276; 2001
	12	Souness et al; Immunopharmacology; 47; 127-162; 2000
	13	Norman, P et al; Expert Opin Ther Patents; 12(1); 93-111; 2002
	14	New Drugs for Respiratory Disease, 5 th International Conference; San Diego, CA USA; July 3-5, 2002
	15	Teixeira et al; Memorias do Instituto Oswaldo Cruz; 92(II); 193-196; 1997
	16	Trifileff et al; Pharmacology Exp Ther.; 301(1); 241-248; 2002
	17	Schmidt, M. et al; J. Allergy Clin Immunol.; 108(4); 530-536; 2001
	18	Spirometry; The Measurement and Interpretation of Ventilatory Function in Clinical Practice; Rob Pierce and David Johns; The Thoratic Society of Australia and New Zealand

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)